First Manhattan’s Clearside Biomedical CLSD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-22,846
| Closed | -$90.7K | – | 736 |
|
|
2025
Q3 | $90.7K | Sell |
22,846
-2
| -0% | -$14 | ﹤0.01% | 703 |
|
|
2025
Q2 | $274K | Hold |
22,848
| – | – | ﹤0.01% | 630 |
|
|
2025
Q1 | $315K | Sell |
22,848
-4,197
| -16% | -$60.3K | ﹤0.01% | 579 |
|
|
2024
Q4 | $385K | Sell |
27,045
-17,364
| -39% | -$286K | ﹤0.01% | 553 |
|
|
2024
Q3 | $846K | Buy |
44,409
+32,742
| +281% | +$559K | ﹤0.01% | 396 |
|
|
2024
Q2 | $228K | Hold |
11,667
| – | – | ﹤0.01% | 613 |
|
|
2024
Q1 | $268K | Hold |
11,667
| – | – | ﹤0.01% | 610 |
|
|
2023
Q4 | $205K | Hold |
11,667
| – | – | ﹤0.01% | 645 |
|
|
2023
Q3 | $152K | Hold |
11,667
| – | – | ﹤0.01% | 698 |
|
|
2023
Q2 | $196K | Hold |
11,667
| – | – | ﹤0.01% | 670 |
|
|
2023
Q1 | $182K | Hold |
11,667
| – | – | ﹤0.01% | 693 |
|
|
2022
Q4 | $196K | Hold |
11,667
| – | – | ﹤0.01% | 706 |
|
|
2022
Q3 | $197K | Hold |
11,667
| – | – | ﹤0.01% | 694 |
|
|
2022
Q2 | $257K | Hold |
11,667
| – | – | ﹤0.01% | 666 |
|
|
2022
Q1 | $400K | Hold |
11,667
| – | – | ﹤0.01% | 626 |
|
|
2021
Q4 | $481K | Hold |
11,667
| – | – | ﹤0.01% | 581 |
|
|
2021
Q3 | $1.05M | Hold |
11,667
| – | – | ﹤0.01% | 424 |
|
|
2021
Q2 | $852K | Hold |
11,667
| – | – | ﹤0.01% | 452 |
|
|
2021
Q1 | $432K | Hold |
11,667
| – | – | ﹤0.01% | 563 |
|
|
2020
Q4 | $479K | Hold |
11,667
| – | – | ﹤0.01% | 520 |
|
|
2020
Q3 | $269K | Hold |
11,667
| – | – | ﹤0.01% | 604 |
|
|
2020
Q2 | $329K | Hold |
11,667
| – | – | ﹤0.01% | 561 |
|
|
2020
Q1 | $297K | Hold |
11,667
| – | – | ﹤0.01% | 552 |
|
|
2019
Q4 | $507K | Hold |
11,667
| – | – | ﹤0.01% | 523 |
|
|
2019
Q3 | $110K | Hold |
11,667
| – | – | ﹤0.01% | 784 |
|
|
2019
Q2 | $170K | Hold |
11,667
| – | – | ﹤0.01% | 735 |
|
|
2019
Q1 | $241K | Hold |
11,667
| – | – | ﹤0.01% | 680 |
|
|
2018
Q4 | $187K | Hold |
11,667
| – | – | ﹤0.01% | 693 |
|
|
2018
Q3 | $1.08M | Hold |
11,667
| – | – | 0.01% | 451 |
|
|
2018
Q2 | $1.87M | Hold |
11,667
| – | – | 0.01% | 374 |
|
|
2018
Q1 | $1.88M | Sell |
11,667
-11,666
| -50% | -$1.42M | 0.01% | 366 |
|
|
2017
Q4 | $2.45M | Hold |
23,333
| – | – | 0.01% | 351 |
|
|
2017
Q3 | $3.06M | Hold |
23,333
| – | – | 0.02% | 316 |
|
|
2017
Q2 | $3.19M | Hold |
23,333
| – | – | 0.02% | 300 |
|
|
2017
Q1 | $2.78M | Buy |
23,333
+16,666
| +250% | +$1.97M | 0.02% | 312 |
|
|
2016
Q4 | $894K | Buy |
+6,667
| New | +$1.67M | 0.01% | 428 |
|
Other funds holding CLSD
First Manhattan's CLSD Position: Q4 2025 in Review
First Manhattan sold out of Clearside Biomedical (CLSD) in Q4 2025, closing a stake of 22,846 shares — an estimated $90.7K sold.
First Manhattan first reported a position in CLSD in Q4 2016 and held it in 36 quarters. The position peaked at $3.19M in Q2 2017. 1 fund tracked by Wall St. Rank holds CLSD as of Q4 2025.
- First Manhattan reported no remaining Clearside Biomedical position as of Q4 2025 after selling out during the quarter.
- First Manhattan sold 22,846 Clearside Biomedical shares in Q4 2025, an estimated $90.7K.
- First Manhattan first reported a position in Clearside Biomedical in Q4 2016 and held it in 36 quarters.
- First Manhattan's Clearside Biomedical position peaked at $3.19M in Q2 2017.
- 1 fund tracked by Wall St. Rank held Clearside Biomedical as of Q4 2025.
Based on First Manhattan's 13F filing for Q4 2025, filed 17 Feb 2026.